PTIX · Protagenic Therapeutics, Inc.\new
$0.57
-0.17 (-22.97%)
At close · Jan 5
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not have sufficient resources to fund its operations past twelve months from the date these consolidated financial statements are available to be issued. The Company expects that additional capital may be required during the next 12 months to continue executing its business plan and to meet its obligations as they become due. Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.45M
Shares
1.81M
PTIX metrics
41 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.57
Market cap
$1.45M
Price action
19 metricsPrice change (1W)
-61.7%
Price change (30D)
—
Price change (3M)
-83.2%
Price change (6M)
-83.2%
Price change (YTD)
-56.2%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
365.4%
Beta
-0.8
RSI (14D)
22.9
Price vs SMA 50
-69.6%
Price vs SMA 200
—
Avg volume (3M)
120,044
Relative volume
4.8
Average dollar volume
$201,510
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
1.81M
Valuation
12 metricsP / E (TTM)
0.4
Trailing earnings · reciprocal yield 250.9%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 118.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
376.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2023-03-31
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$4.26M
Net income (TTM)
$5.46M
Trailing 12 months
Diluted EPS (TTM)
$1.43
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-51.1%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
316.9%
Return on assets
195.3%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$565,985
Total assets
$2.80M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$2.00M
Capital expenditures (TTM)
—
R&D (TTM)
$617,709
SG&A (TTM)
—
Stock compensation (TTM)
$360,474
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
2
13F filer change QoQ
-2
Institutional ownership
3.7%
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
$30,717
Insider-sentiment score
83 / 100
Risk flags
1 metricsGoing concern
Flagged